Rapid, Near-Tranfusion Test for Bacteria in Platelets Units

快速、近输血检测血小板单位中的细菌

• 批准号: 8700470
• 负责人: Andrew E. Levin
• 金额: $ 98.91万
• 依托单位: IMMUNETICS, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-06 至 2015-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8700470
• 关键词: Address; American; Automation; Bacteria; Biological Assay; Blood Banks; Blood Platelets; Centrifugation; Chemistry; Clinical; Clinical Research; Clinical Trials; Collaborations; Computer software; Critical Illness; Detection; Development; Device or Instrument Development; Devices; Drug Formulations; Engineering; Evaluation; FDA approved; Generations; Goals; Gram-Negative Bacteria; Guidelines; HIV; Health; Hospitals; Human Resources; In Vitro; Lead; Length; Leukocytes; Life; Measurable; Measurement; Medical; Methods; Morbidity - disease rate; Outcome; Patients; Performance; Phase; Platelet Transfusion; Policies; Preparation; Protocols documentation; Quality Control; Reaction; Reagent; Risk; Running; Sampling; Sensitivity and Specificity; Shipping; Ships; Specificity; Sterility; System; Technology; Test Result; Testing; Time; Transfusion; Validation; Whole Blood; base; blood product; commercialization; cost; design; experience; hospital laboratories; innovation; instrument; meetings; mortality; operation; prevent; prototype; public health relevance; reagent testing; screening; septic; software development

DESCRIPTION (provided by applicant): Bacterial contamination of platelets is considered the greatest infectious risk of blood product transfusion today at about 1 in 2000 platelet units, which is several orders of magnitude greater than that of HIV. Bacterial contamination at high levels can lead to severe morbidity or mortality in transfusion recipients. The American Association of Blood Banks issued directives in 2004 and 2011 requiring bacterial testing on all platelet units. Two recent studies have demonstrated that current FDA-approved culture-based methods that test for contamination 1 to 4 days prior to transfusion miss a majority of contaminated units. The time elapsed between sampling and actual transfusion and the associated risk of bacterial contamination is a fundamental problem that cannot be addressed by current culture-based platelet testing. A rapid and sensitive point-of-issue test for bacterial contamination would overcome this problem by providing an assessment of potential contamination immediately prior to transfusion. Such a test would be used by a hospital laboratory close to the point of transfusion or by a transfusion center preparing to ship platelet units to a clinical center. A rapid test would ideally require less than 15 min, have detection sensitivity of 104 CFU/mL or better, be fully automated, and be comparable in cost to current tests. BacTx technology, developed by Immunetics for detection of bacterial contamination in platelets, employs a unique and innovative assay chemistry capable of rapidly detecting both Gram-positive and Gram-negative bacteria in platelet units. The first-generation BacTx Bacterial Detection Kit recently received clearance from FDA (CBER) as a quality control test for pooled, leukocyte-reduced whole blood derived platelets, but this test is not ideally suited for use as a point of issue test due to its length (45 min) and complexity (requiring centrifugation and accurate pipetting). In the Phase I project, we successfully demonstrated feasibility of a simple, filter-based BacTx assay which is rapid (<15 min) and highly amenable to automation, while maintaining the high sensitivity and specificity of the original BacTx test. In Phase II, we will optimize and configure the rapid test for automated performance and will design, build and evaluate prototype instruments and software to run the test. The instrument and software development will be carried out in collaboration with engineering partners who have many years of experience in the development of medical test systems with comparable functionality. At the conclusion of Phase II, we will have developed and validated an integrated rapid BacTx test system ready for clinical studies aimed at 510(k) approval. Commercialization of this rapid test will enable a paradigm shift in platelet testing and a significant reduction in the number of bacterially contaminated platelet units transfused into critically ill patients. Furthermore, adopton of the rapid BacTx test could ultimately lead to a change in policy regarding platelets, significantly reducing costs for blood banks by allowing an extension of the storage life of platelet units from 5 to 7 days.

描述（由申请人提供）：血小板的细菌污染被认为是当今输血产品的最大感染风险，约为1 / 2000血小板单位，比HIV高出几个数量级。高水平的细菌污染可导致接受输血者严重的发病率或死亡率。美国血库协会（American Association of Blood Banks）在2004年和2011年发布指令，要求对所有血小板单位进行细菌检测。最近的两项研究表明，目前fda批准的基于培养的方法在输血前1至4天检测污染，错过了大多数污染单位。采样和实际输血之间的时间间隔以及相关的细菌污染风险是目前基于培养的血小板检测无法解决的基本问题。一种快速而敏感的细菌污染检测方法可以在输血前立即对潜在污染进行评估，从而克服这一问题。这种测试将由靠近输血点的医院实验室或输血中心准备运送血小板单位到临床中心使用。理想情况下，快速测试需要不到15分钟，检测灵敏度为104 CFU/mL或更高，完全自动化，成本与当前测试相当。BacTx技术是由Immunetics公司开发的用于检测血小板细菌污染的技术，它采用了一种独特和创新的分析化学方法，能够快速检测血小板单位中的革兰氏阳性和革兰氏阴性细菌。第一代BacTx细菌检测试剂盒最近获得了FDA （CBER）的批准，作为汇集的、白细胞减少的全血来源血小板的质量控制测试，但由于其长度（45分钟）和复杂性（需要离心和精确移液），该测试不适合用作问题点测试。在I期项目中，我们成功证明了一种简单的、基于过滤器的BacTx检测方法的可行性，该方法快速（<15分钟）且高度自动化，同时保持了原始BacTx测试的高灵敏度和特异性。在第二阶段，我们将优化和配置自动化性能的快速测试，并将设计、构建和评估运行测试的原型仪器和软件。仪器和软件开发将与工程合作伙伴合作进行，这些合作伙伴在开发具有类似功能的医学测试系统方面具有多年经验。在II期结束时，我们将开发并验证一个集成的快速BacTx测试系统，为临床研究做好准备，旨在获得510(k)批准。这种快速检测的商业化将使血小板检测的模式发生转变，并显著减少输注到危重患者体内的被细菌污染的血小板单位的数量。此外，快速BacTx检测的采用可能最终导致血小板政策的改变，通过将血小板单位的储存寿命从5天延长到7天，显著降低血库的成本。